Select therapeutic use:

Bleeding disorders:

Indications for: DDAVP INJECTION

To maintain hemostasis or to stop bleeding in Hemophilia A and mild to moderate Type 1 von Willebrand's disease (VWD), each with >5% Factor VIII activity.

Adults and Children:

<3months: not recommended. ≥3months: 0.3micrograms/kg IV over 15–30mins. Pre-op: give 30mins before scheduled procedure. May repeat dose based on clinical response. Repeated administration before 48hrs associated with tachyphylaxis.

DDAVP INJECTION Contraindications:

Moderate to severe renal impairment (CrCl <50mL/min). Hyponatremia, or history of.

DDAVP INJECTION Warnings/Precautions:

Not for treating Hemophilia A with Factor VIII coagulant activity levels ≤5%, Hemophilia B, in patients with FVIII antibodies, or for Type IIB VWD, or severe Type 1 VWD and evidence of abnormal molecular form of FVIII antigen. Monitor fluid intake, urine volume plasma osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Adjust fluid intake downward (esp in children and elderly) to decrease risk of water intoxication, hyponatremia. Habitual or psychogenic polydipsia. Coronary artery insufficiency. Hypertension. Predisposition to thrombosis. Pregnancy (Cat.B). Nursing mothers.

DDAVP INJECTION Classification:

Antidiuretic hormone.

DDAVP INJECTION Interactions:

Caution with other pressor agents, drugs that may increase the risk of water intoxication with hyponatremia (eg, tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine, carbamazepine). Possible convulsions with oxybutynin, imipramine.

Adverse Reactions:

Headache, nausea, flushing, abdominal cramps, vulval pain, inj site reaction, water intoxication, hyponatremia, rare: changes in BP, severe allergic reactions, thrombotic events (inj).

How Supplied:

Amp (1mL)—10; Multi-dose vial (10mL)—1

Pituitary disorders:

Indications for: DDAVP INJECTION

Central (cranial) diabetes insipidus. Temporary polyuria and polydipsia following head trauma or surgery in the pituitary region.

Adult Dosage:

2–4mcg/day SC or IV in 2 divided doses. If switching stabilized patient, use one-tenth of intranasal dose.

Children Dosage:

Not established.

DDAVP INJECTION Contraindications:

Moderate to severe renal impairment (CrCl <50mL/min). Hyponatremia, or history of.

DDAVP INJECTION Warnings/Precautions:

Monitor fluid intake, urine volume and osmolality. Fluid/electrolyte imbalance (eg, cystic fibrosis). Habitual or psychogenic polydipsia. Coronary artery insufficiency. Hypertension. Inj: Predisposition to thrombosis. Nasal mucosal abnormalities (nasal forms). Young children. Elderly. Pregnancy. Nursing mothers.

DDAVP INJECTION Classification:

Vasopressin (synthetic).

DDAVP INJECTION Interactions:

Caution with other pressor agents, drugs that may increase the risk of water intoxication with hyponatremia (eg, tricyclic antidepressants, SSRIs, chlorpromazine, opiates, NSAIDs, lamotrigine, carbamazepine). Possible convulsions with oxybutynin, imipramine.

Adverse Reactions:

Headache, nausea, flushing, abdominal cramps, vulval pain, water intoxication, hyponatremia, nasal congestion or rhinitis (nasal forms), inj site reaction; rare: changes in BP, severe allergic reactions, seizures in children from plasma hypoosmolality, thrombotic events (inj).

How Supplied:

Tabs—100; Rhinal tube—2.5mL (w. 2 rhinal tubes); Amp (1mL)—10; Multi-dose vial (10mL)—1; Nasal spray—5mL (50 sprays)